Regeneron Reports registry Data for Crizotinib in Chronic lymphocytic leukemia

Regeneron today announced registry results for crizotinib in patients with chronic lymphocytic leukemia. The study demonstrated that crizotinib demonstrates safety and tolerability compared to standard of care or placebo. These results provide important insights into the treatment of chronic lymphocytic leukemia and support the continued development of crizotinib in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.